Pharmacopsychiatry

Keyphrases

Publications

2024

Yuki Komatsu, Moe Takehara, Xenia Hart, Yuna Takahashi, Satoko Hori, Fumihiko Ueno, Hiroyuki Uchida
Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments. Pharmacopsychiatry (2024)
Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker, Jürgen Deckert, Helge Frieling, Heike Weber
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry (2024)
Talar A Merza Mohammad, Tavgah A Merza Mohammad, Dyar M Salman, Halmat M Jaafar
Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry (2024)
Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry (2024)
Mohsen Khosravi, Abdullah A Alzahrani, Thikra M Muhammed, Ahmed Hjazi, Huda H Abbas, Mervat A AbdRabou, Karrar H Mohmmed, Pallavi Ghildiyal, Alexey Yumashev, Ahmed Elawady, Sahel Sarabandi
Management of Refractory Functional Gastrointestinal Disorders: What Role Should Psychiatrists Have? Pharmacopsychiatry (2024)
Inga Dammann, Cathrin Rohleder, F Markus Leweke
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review. Pharmacopsychiatry (2024)
Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression. Pharmacopsychiatry (2024)
Vicent Llorca-Bofí, Miquel Bioque, Santiago Madero, Andrea Mallorquí, Cristina Oliveira, Marina Garriga, Eduard Parellada, Clemente García-Rizo
Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder. Pharmacopsychiatry (2024)
Matthias Karst
Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry (2024)
Teruo Tada, Takefumi Suzuki, Yusuke Iwata, Masaharu Kubota, Koichiro Watanabe, Hitoshi Sakurai
A Trajectory of Long-Term Antipsychotic Medication Dosage in Inpatients with Severe Behavioral and Psychological Symptoms of Dementia: A Retrospective Study. Pharmacopsychiatry (2024)
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry (2024)
Matthias Karst
Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry (2024)
Xenia M Hart, Yasue Mitsukura, Robert R Bies, Hiroyuki Uchida
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis. Pharmacopsychiatry (2024)
Yuna Takahashi, Taisuke Yatomi, Naohito Yamaguchi, Kimio Yoshimura, Satoko Hori, Hiroyuki Uchida
Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection. Pharmacopsychiatry (2024)
Kirsten R Müller-Vahl
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry (2024)

volume 57, number 2, 2024

Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry 57 (2) (2024)
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry 57 (2) (2024)
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry 57 (2) (2024)
Xenia M Hart, Yasue Mitsukura, Robert R Bies, Hiroyuki Uchida
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis. Pharmacopsychiatry 57 (2) (2024)
Michael Specka, Udo Bonnet, Lisa Schmidberg, Julian Wichmann, Martin Keller, Christian Scholze, Norbert Scherbaum
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study. Pharmacopsychiatry 57 (2) (2024)
Scott Monteith, Tasha Glenn, John R Geddes, Peter C Whybrow, Eric D Achtyes, Michael Bauer
Implications of Online Self-Diagnosis in Psychiatry. Pharmacopsychiatry 57 (2) (2024)
Dhouha Sahnoun, Ahlem Ghanmi, Soumaya Gazzeh, Bochra Saguem, Raoudha Slim, Jaafar Nakhli, Chaker Ben Salem
Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature. Pharmacopsychiatry 57 (2) (2024)
Xenia M Hart, Yasue Mitsukura, Robert R Bies, Hiroyuki Uchida
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis. Pharmacopsychiatry 57 (2) (2024)
Michael Specka, Udo Bonnet, Lisa Schmidberg, Julian Wichmann, Martin Keller, Christian Scholze, Norbert Scherbaum
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study. Pharmacopsychiatry 57 (2) (2024)
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry 57 (2) (2024)
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry 57 (2) (2024)
Scott Monteith, Tasha Glenn, John R Geddes, Peter C Whybrow, Eric D Achtyes, Michael Bauer
Implications of Online Self-Diagnosis in Psychiatry. Pharmacopsychiatry 57 (2) (2024)
Dhouha Sahnoun, Ahlem Ghanmi, Soumaya Gazzeh, Bochra Saguem, Raoudha Slim, Jaafar Nakhli, Chaker Ben Salem
Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature. Pharmacopsychiatry 57 (2) (2024)

volume 57, number 3, 2024

Inga Dammann, Cathrin Rohleder, F Markus Leweke
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review. Pharmacopsychiatry 57 (3) (2024)
Kirsten R Müller-Vahl
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry 57 (3) (2024)
Kirsten R Müller-Vahl
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry 57 (3) (2024)
Barbara Broers, Federica Bianchi
Cannabinoids for Behavioral Symptoms in Dementia: An Overview. Pharmacopsychiatry 57 (3) (2024)
Matthias Karst
Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry 57 (3) (2024)
Inga Dammann, Cathrin Rohleder, F Markus Leweke
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review. Pharmacopsychiatry 57 (3) (2024)
Ankita Das, Christian S Hendershot, M Ishrat Husain, Yuliya Knyahnytska, Sonja Elsaid, Bernard Le Foll, Stefan Kloiber
Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada - A Qualitative Study. Pharmacopsychiatry 57 (3) (2024)
Kirsten R Müller-Vahl
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry 57 (3) (2024)
Matthias Karst
Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry 57 (3) (2024)
Kirsten R Müller-Vahl, Georg Juckel
Medical Cannabis in Psychiatry. Pharmacopsychiatry 57 (3) (2024)
Barbara Broers, Federica Bianchi
Cannabinoids for Behavioral Symptoms in Dementia: An Overview. Pharmacopsychiatry 57 (3) (2024)
Matthias Karst
Overview: Chronic Pain and Cannabis-Based Medicines. Pharmacopsychiatry 57 (3) (2024)

volume 57, number 4, 2024

Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry 57 (4) (2024)
Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker, Jürgen Deckert, Helge Frieling, Heike Weber
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry 57 (4) (2024)
Talar A Merza Mohammad, Tavgah A Merza Mohammad, Dyar M Salman, Halmat M Jaafar
Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry 57 (4) (2024)
Yuna Takahashi, Taisuke Yatomi, Naohito Yamaguchi, Kimio Yoshimura, Satoko Hori, Hiroyuki Uchida
Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection. Pharmacopsychiatry 57 (4) (2024)
Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry 57 (4) (2024)
Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry 57 (4) (2024)
Vicent Llorca-Bofí, Miquel Bioque, Santiago Madero, Andrea Mallorquí, Cristina Oliveira, Marina Garriga, Eduard Parellada, Clemente García-Rizo
Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder. Pharmacopsychiatry 57 (4) (2024)
Talar A Merza Mohammad, Tavgah A Merza Mohammad, Dyar M Salman, Halmat M Jaafar
Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Pharmacopsychiatry 57 (4) (2024)
Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker, Jürgen Deckert, Helge Frieling, Heike Weber
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry 57 (4) (2024)
Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker, Jürgen Deckert, Helge Frieling, Heike Weber
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group. Pharmacopsychiatry 57 (4) (2024)